- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Parkinson Disease Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Parkinson Disease Drug business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Parkinson Disease Drug market by product type, application, key companies and key regions.
This study considers the Parkinson Disease Drug value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Merck
Desitin Arzneimittel
Akorn
Novartis
Boehringer Ingelheim
GSK
Kyowa Hakko Kirin Pharma
Teva Pharmaceutical
Astellas Pharma
Abbvie
Orion
US WorldMeds
Stada Arzneimittel
Endo Pharmaceuticals
Valeant
H.Lundbeck
Apokyn
F.Hoffmann-La Roche
Bausch Health
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Parkinson Disease Drug market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Parkinson Disease Drug market by identifying its various subsegments.
Focuses on the key global Parkinson Disease Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Parkinson Disease Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Parkinson Disease Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
Global Parkinson Disease Drug Market Growth (Status and Outlook) 2019-2024
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Parkinson Disease Drug Market Size 2014-2024
2.1.2 Parkinson Disease Drug Market Size CAGR by Region
2.2 Parkinson Disease Drug Segment by Type
2.2.1 Sinemet-CR
2.2.2 Sinemet-CR
2.2.3 Madopar
2.2.4 COMT Inhibitor
2.2.5 Other
2.3 Parkinson Disease Drug Market Size by Type
2.3.1 Global Parkinson Disease Drug Market Size Market Share by Type (2014-2019)
2.3.2 Global Parkinson Disease Drug Market Size Growth Rate by Type (2014-2019)
2.4 Parkinson Disease Drug Segment by Application
2.4.1 Under 40 Years Old
2.4.2 40-65 Years Old
2.4.3 Above 65 Years Old
2.5 Parkinson Disease Drug Market Size by Application
2.5.1 Global Parkinson Disease Drug Market Size Market Share by Application (2014-2019)
2.5.2 Global Parkinson Disease Drug Market Size Growth Rate by Application (2014-2019)
3 Global Parkinson Disease Drug by Players
3.1 Global Parkinson Disease Drug Market Size Market Share by Players
3.1.1 Global Parkinson Disease Drug Market Size by Players (2017-2019)
3.1.2 Global Parkinson Disease Drug Market Size Market Share by Players (2017-2019)
3.2 Global Parkinson Disease Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Parkinson Disease Drug by Regions
4.1 Parkinson Disease Drug Market Size by Regions
4.2 Americas Parkinson Disease Drug Market Size Growth
4.3 APAC Parkinson Disease Drug Market Size Growth
4.4 Europe Parkinson Disease Drug Market Size Growth
4.5 Middle East & Africa Parkinson Disease Drug Market Size Growth
5 Americas
5.1 Americas Parkinson Disease Drug Market Size by Countries
5.2 Americas Parkinson Disease Drug Market Size by Type
5.3 Americas Parkinson Disease Drug Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Parkinson Disease Drug Market Size by Countries
6.2 APAC Parkinson Disease Drug Market Size by Type
6.3 APAC Parkinson Disease Drug Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Parkinson Disease Drug by Countries
7.2 Europe Parkinson Disease Drug Market Size by Type
7.3 Europe Parkinson Disease Drug Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Parkinson Disease Drug by Countries
8.2 Middle East & Africa Parkinson Disease Drug Market Size by Type
8.3 Middle East & Africa Parkinson Disease Drug Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Parkinson Disease Drug Market Forecast
10.1 Global Parkinson Disease Drug Market Size Forecast (2019-2024)
10.2 Global Parkinson Disease Drug Forecast by Regions
10.2.1 Global Parkinson Disease Drug Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Parkinson Disease Drug Forecast by Type
10.8 Global Parkinson Disease Drug Forecast by Application
11 Key Players Analysis
11.1 Merck
11.1.1 Company Details
11.1.2 Parkinson Disease Drug Product Offered
11.1.3 Merck Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 Merck News
11.2 Desitin Arzneimittel
11.2.1 Company Details
11.2.2 Parkinson Disease Drug Product Offered
11.2.3 Desitin Arzneimittel Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 Desitin Arzneimittel News
11.3 Akorn
11.3.1 Company Details
11.3.2 Parkinson Disease Drug Product Offered
11.3.3 Akorn Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 Akorn News
11.4 Novartis
11.4.1 Company Details
11.4.2 Parkinson Disease Drug Product Offered
11.4.3 Novartis Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 Novartis News
11.5 Boehringer Ingelheim
11.5.1 Company Details
11.5.2 Parkinson Disease Drug Product Offered
11.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 Boehringer Ingelheim News
11.6 GSK
11.6.1 Company Details
11.6.2 Parkinson Disease Drug Product Offered
11.6.3 GSK Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 GSK News
11.7 Kyowa Hakko Kirin Pharma
11.7.1 Company Details
11.7.2 Parkinson Disease Drug Product Offered
11.7.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 Kyowa Hakko Kirin Pharma News
11.8 Teva Pharmaceutical
11.8.1 Company Details
11.8.2 Parkinson Disease Drug Product Offered
11.8.3 Teva Pharmaceutical Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 Teva Pharmaceutical News
11.9 Astellas Pharma
11.9.1 Company Details
11.9.2 Parkinson Disease Drug Product Offered
11.9.3 Astellas Pharma Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.9.4 Main Business Overview
11.9.5 Astellas Pharma News
11.10 Abbvie
11.10.1 Company Details
11.10.2 Parkinson Disease Drug Product Offered
11.10.3 Abbvie Parkinson Disease Drug Revenue, Gross Margin and Market Share (2017-2019)
11.10.4 Main Business Overview
11.10.5 Abbvie News
11.11 Orion
11.12 US WorldMeds
11.13 Stada Arzneimittel
11.14 Endo Pharmaceuticals
11.15 Valeant
11.16 H.Lundbeck
11.17 Apokyn
11.18 F.Hoffmann-La Roche
11.19 Bausch Health
12 Research Findings and Conclusion
List of Tables and Figures
Table Product Specifications of Parkinson Disease Drug
Figure Parkinson Disease Drug Report Years Considered
Figure Market Research Methodology
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
